Analysis

Nextcure, Inc. (NXTC) Stock Analysis

Nextcure, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to NXTC.

websiteNXTC/analysis/NXTC

Nextcure, Inc.

Nextcure, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to NXTC.

Stock profile

Ticker

NXTC

Asset type

Stock

Market cap

$7.3M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Nextcure, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • NXTC primary listing
  • 2US0
  • A41AKJ

Latest Nextcure, Inc. news

NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecol...

NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg)Favorable sa...

NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

SIM0505/CDH6 ADC dose optimization initiated in gynecologic cancersSIM0505 Phase 1 dose escalation study data to be presented at ASCO 2026 LNCB74 Phase 1 dose escalation trial u...

NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers

Dose optimization will initially be focused on evaluating SIM0505 in patients with platinum-resistant ovarian cancer (PROC) Phase 1 data readout to be presented at ASCO 2026 BEL...

NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) Phase 1 data f...

Research sections

Valuation

Review valuation context for Nextcure, Inc..

Future growth

Review future growth context for Nextcure, Inc..

Past performance

Review past performance context for Nextcure, Inc..

Financial health

Review financial health context for Nextcure, Inc..

Dividend

Review dividend context for Nextcure, Inc..

Management

Review management context for Nextcure, Inc..

Ownership

Review ownership context for Nextcure, Inc..

Other information

Review other information context for Nextcure, Inc..

Community

Review community context for Nextcure, Inc..